Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Sanofi

Status and phase: Completed; Phase 2; Phase 1

Conditions: Meningococcal Meningitis; Meningococcal Infections

Treatments: Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; Biological: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00874549

MTA29

Details and patient eligibility

About

Safety:

To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination with either Menactra® vaccine or Menomune® vaccine.

Immunogenicity:

To evaluate the immune response to serogroups A, C, Y, and W-135 in each of the four study groups.

Enrollment: 216 patients

Sex: All

Ages: 56+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Ambulatory and healthy, as determined by medical history.
• 56 years of age or older at the time of vaccination.
• Signed Institutional Review Board (IRB)-approved informed consent form.
• Able to attend all scheduled visits and to comply with all trial procedures.
• For a woman, inability to become pregnant or a negative urine pregnancy test at the time of enrollment.

Exclusion criteria

• Any condition which, in the opinion of the Investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
• Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc) that is unstable or that might 1) interfere with the ability to participate fully in the study or 2) interfere with evaluation of the vaccines.
• Known or suspected impairment of immunologic function.
• Febrile illness within the last 72 hours or an oral temperature ≥ 100.4ºF at the time of inclusion.
• History of documented invasive meningococcal disease or previous meningococcal vaccination.
• Known or suspected receipt of a diphtheria-containing vaccine within the preceding 2 years.
• Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
• Systemic antibiotic therapy within the 72 hours prior to collection of any blood samples.
• Received any vaccine in the 28-day period prior to enrollment or scheduled to receive any vaccination through Visit 2 for Groups 1 and 2 and through Visit 3 for Groups 3 and 4. Influenza vaccines may be received 2 weeks before or after a study vaccination.
• Suspected or known hypersensitivity to latex or to any of the components of either Menactra® vaccine or Menomune® vaccine.
• Previous personal history of Guillain-Barré syndrome.
• Not available for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
• In females of childbearing potential, a positive or equivocal urine pregnancy test at enrollment.
• A nursing mother.
• Participation in another interventional clinical trial in the 4 weeks preceding enrollment or planning to participate in another interventional clinical trial during the planned period of this study.
• Current use of alcohol or recreational drugs that may interfere with the subject's ability to comply with trial visits or procedures.
• Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.
• Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

216 participants in 4 patient groups

Group 1: Menomune Day 0

Active Comparator group

Description:

Participants received a single dose of Menomune® vaccine on Day 0.

Treatment:

Biological: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide

Group 2: Menactra® Day 0 x 2

Experimental group

Description:

Participants received two single-dose injections of Menactra® vaccine on Day 0

Treatment:

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Group 3: Menactra® Day 0 and 14

Experimental group

Description:

Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14

Treatment:

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Group 4: Menactra® Day 0 and 28

Experimental group

Description:

Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.

Treatment:

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate